During clinical trials, IL-blocking antibodies have been reported to reduce the number of acute exacerbations and methods that inhibit upstream cytokines, such as thymic stromal lymphopoietin (TSLP), and have the potential to improve patient health in COPD [65]. This evidence concerns the gene TSLP and chronic obstructive pulmonary disease.